Search Patents
  • 3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS
    Publication number: 20130245355
    Abstract: Compounds of the formula I in which Q, R1, R2, R3 and R4 have the meanings indicated in Claim 1, are PDK1 inhibitors and can be employed for the treatment of tumours.
    Type: Application
    Filed: November 17, 2011
    Publication date: September 19, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Hans-Peter Buchstaller, Margarita Wucherer-Plietker, Timo Heinrich
  • PYRIMIDINE DERIVATIVES AS FAK INHIBITORS
    Publication number: 20130158005
    Abstract: Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: July 19, 2011
    Publication date: June 20, 2013
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Timo Heinrich, Christina Esdar, Hartmut Greiner
  • 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS
    Publication number: 20100273796
    Abstract: Compounds of the formula I in which R1, R2, R3, R4? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: November 25, 2008
    Publication date: October 28, 2010
    Applicant: Merck Patent Gesellschaft MIT Beschrankter Haftung
    Inventors: Dieter Dorsch, Oliver Schadt, Andree Blaukat
  • Pyrrolopyridinylpyrimidin-2-ylamine derivatives
    Patent number: 8575163
    Abstract: Pyrrolopyridinylpyrimidin-2-ylamine derivatives of the formula (I), in which R1-R6 and R1 have the meanings indicated in claim 1, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: November 5, 2013
    Assignee: Merck Patent GmbH
    Inventors: Margarita Wucherer-Plietker, Christina Esdar, Brian Hodous
  • Fluorinated indenes and 1,7-dihydroindacenes of negative dielectric anisotrophy
    Publication number: 20030222243
    Abstract: Fluorinated indenes and 1,7-dihydroindacenes of the general formulae (I) and (II) of negative dielectric anisotropy (&Dgr;&egr;<0) 1
    Type: Application
    Filed: April 4, 2003
    Publication date: December 4, 2003
    Applicant: Merck Patent GmbH
    Inventors: Lars Lietzau, Melanie Klasen-Memmer, Matthias Bremer
  • 2-benzylpyridazinone derivatives as met kinase inhibitors
    Patent number: 8557813
    Abstract: Compounds of the formula I in which R1, R2, R3, R4? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: October 15, 2013
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Oliver Schadt, Frank Stieber, Andree Blaukat
  • Intermediates and process for the synthesis of azasteroids
    Patent number: 6187925
    Abstract: The novel process of this invention involves the stereoselective synthesis of certain 16-substituted 4-aza-5&agr;-androst-1-en-3-ones, and the useful intermediates obtained therein.
    Type: Grant
    Filed: December 16, 1998
    Date of Patent: February 13, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Guy R. Humphrey, Ross A. Miller, Wenjie Li
  • PYRIDAZINONE DERIVATIVES
    Publication number: 20130184260
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R4? have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: March 5, 2013
    Publication date: July 18, 2013
    Inventor: Merck Patent Gesellschaft Mit Beschrankter Haftung
  • PYRIDAZINONE DERIVATIVES
    Publication number: 20100179148
    Abstract: Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: May 2, 2008
    Publication date: July 15, 2010
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Frank Stieber, Oliver Schadt, Dieter Dorsch, Andree Blaukat
  • Chiral compounds
    Patent number: 5180521
    Abstract: Optically active compounds of the formula I can be used as components of chiral tilted smectic liquid crystal phases.
    Type: Grant
    Filed: July 2, 1990
    Date of Patent: January 19, 1993
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Rudolf Eidenschink, Reinhard Hopf, Eike Poetsch
  • PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES
    Publication number: 20120270871
    Abstract: Pyrrolopyridinylpyrimidin-2-ylamine derivatives of the formula (I), in which R1-R6 and R1 have the meanings indicated in claim 1, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Application
    Filed: October 12, 2010
    Publication date: October 25, 2012
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Margarita Wucherer-Plietker, Christina Esdar, Brian Hodous
  • Pyridazinone derivatives
    Patent number: 8580781
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R4? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: November 12, 2013
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Frank Stieber, Oliver Schadt, Andree Blaukat
  • Antagonists of gonadotropin releasing hormone
    Patent number: 6077847
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: June 20, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Thomas F. Walsh, Mark T. Goulet, Feroze Ujjainwalla
  • ARYL ETHER PYRIDAZINONE DERIVATIVES
    Publication number: 20100179149
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: May 2, 2008
    Publication date: July 15, 2010
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG
    Inventors: Frank Stieber, Oliver Schadt, Dieter Dorsch, Andree Blaukat
  • Fused polycyclic and bridged compounds useful as calcium channel blockers
    Patent number: 4808718
    Abstract: Novel fused polycyclic and bridged compounds are disclosed which are useful as calcium entry blockers.
    Type: Grant
    Filed: May 6, 1986
    Date of Patent: February 28, 1989
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Wasyl Halczenko, Brian T. Phillips
  • AZAHETEROCYCLIC COMPOUNDS
    Publication number: 20150005294
    Abstract: The invention provides novel substituted azaheterocyclic compounds compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.
    Type: Application
    Filed: January 10, 2013
    Publication date: January 1, 2015
    Applicants: CANCER RESEARCH TECHNOLOGY LIMITED, MERCK PATENT GMBH
    Inventors: Kai Schiemann, Frank Stieber, Christina Esdar
  • Substituted 4-hydroxypyrimidine-5-carboxamides
    Patent number: 8278304
    Abstract: The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: October 2, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Matthew J. Clements, John S. Debenham, Jeffrey J. Hale, Christina B. Madsen-Duggan, Thomas F. Walsh
  • Compounds having cytokine inhibitory activity
    Patent number: 6350744
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: November 4, 1999
    Date of Patent: February 26, 2002
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, Gerald S. Ponticello
  • Process for the stereoselective synthesis of 16-substituted-4-aza-androstanones
    Patent number: 6143887
    Abstract: The novel process of the present invention involves the stereoselective synthesis of certain 16.beta.-substituted 4-aza-5.alpha.-androstan-3-ones and the useful intermediates obtained therein.
    Type: Grant
    Filed: May 11, 1999
    Date of Patent: November 7, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Dominick F. Gratale, Richard L. Tolman, Soumya P. Sahoo
  • PYRIDAZINONE DERIVATIVES
    Publication number: 20100234354
    Abstract: Compounds of the formula (I), in which R1, R2, R, R4, R4? have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: April 29, 2008
    Publication date: September 16, 2010
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Dieter Dorsch, Frank Stieber, Oliver Schadt, Andree Blaukat